Article
Non-inferiority trials using a surrogate marker as the primary endpoint: An increasing phenotype in cardiovascular trials.
Clinical trials (London, England) - 1 Dec 2020
Bikdeli Behnood, Caraballo César, Welsh John, Ross Joseph S, Kaul Sanjay, Stone Gregg W, Krumholz Harlan M
Abstract excerpt
BACKGROUND/AIMS: Non-inferiority trials are increasing in cardiovascular medicine, with approval of many drugs and devices on the basis of such studies. Surrogate markers as primary endpoints have been also more frequently used for efficient assessment of cardiovascular interventions. However, there is uncertainty about their concordance with clinical outcomes. Non-inferiority design using a surrogate marker as a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.